Hypopituitarism News and Research

RSS

Hypopituitarism is a health condition in which there is a reduction in the production of hormones by the pituitary gland.

The impact of viral infections on the human endocrine system

Researchers briefly outlined how viral infections trigger endocrinopathies in humans.

3 Feb 2023

Hypopituitarism and COVID-19 – exploring a possible bidirectional relationship?

In a recent study published in Reviews in Endocrine and Metabolic Disorders, the researchers discuss the extra-pulmonary manifestations of COVID-19.

5 Sep 2021

POU1F1 gene variant linked to pituitary dwarfism in Karelian Bear Dogs

A study carried out at the University of Helsinki investigated pituitary dwarfism in Karelian Bear Dogs and found a link to a variant of the POU1F1 gene. The results can also help understand the gene's significance to the human pituitary gland's development and function.

22 Feb 2021

Individuals taking glucocorticoids are at high risk if infected with COVID-19

Individuals taking a class of steroid hormones called glucocorticoids for conditions such as asthma, allergies and arthritis on a routine basis may be unable to mount a normal stress response and are at high risk if they are infected with the virus causing COVID-19, according to a new editorial published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism.

31 Mar 2020

Scientists create world’s first model of pituitary disease using human iPS cells

Researchers at Kobe University's Graduate School of Medicine have developed the world's first congenital pituitary hypoplasia model using patient-derived iPS cells.

14 Feb 2020

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Bristol-Myers Squibb Company today announced four-year data from the Phase 3 CheckMate -067 clinical trial - the longest follow-up to date - which continues to demonstrate durable, long-term survival benefits with the first-line combination of Opdivo (nivolumab) and Yervoy (ipilimumab), versus Yervoy alone, in patients with advanced melanoma.

22 Oct 2018

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck, known as MSD outside the United States and Canada, today announced the first presentation of preliminary data from a Phase 1 clinical trial evaluating MK-1454, an investigational STING (stimulator of interferon genes) agonist, as monotherapy and in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced solid tumors or lymphomas.

22 Oct 2018

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck, known as MSD outside the United States and Canada, today announced the first presentation of results from an interim analysis of KEYNOTE-057, a Phase 2 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, for previously treated patients with high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ or CIS plus papillary disease (Cohort A).

22 Oct 2018

CNDA approves KEYTRUDA for treatment of advanced melanoma

Merck, known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck's anti-PD-1 therapy, has been approved by the China National Drug Administration for the treatment of adult patients with unresectable or metastatic melanoma following failure of one prior line of therapy.

26 Jul 2018

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Merck, known as MSD outside the United States and Canada, announced today that the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma, met a primary endpoint of overall survival as monotherapy in patients whose tumors expressed PD-L1.

25 Jul 2018

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted for standard review a new supplemental Biologics License Application for KEYTRUDA, Merck's anti-PD-1 therapy, as adjuvant therapy in the treatment of patients with resected, high-risk stage III melanoma and granted a Prescription Drug User Fee Act, or target action, date of February 16, 2019.

25 Jun 2018

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

Bristol-Myers Squibb Company today announced patient-reported outcomes data from the Phase 3 CheckMate -214 trial in intermediate- and poor-risk patients with advanced renal cell carcinoma treated with the Immuno-Oncology combination Opdivo plus low-dose Yervoy versus sunitinib over a two-year follow-up period.

1 Jun 2018

First-ever treatment for Merkel cell carcinoma receives approval in Japan

Merck KGaA, Darmstadt, Germany, and Pfizer Inc. today announced that the Japanese Ministry of Health, Labor, and Welfare (MHLW) has approved BAVENCIO (avelumab, genetically recombinant Injection 200mg/mL for intravenous use) as the first and only treatment indicated for curatively unresectable Merkel cell carcinoma (MCC), a rare and aggressive cancer, in Japan.

27 Sep 2017

Newly-identified autoimmune endocrine disease is caused by thymomas, study finds

A Japanese research group has discovered that a newly-identified autoimmune endocrine disease that leads to hypopituitarism is caused by thymomas (a type of tumor originating from the thymic gland).

2 Mar 2017

People with reduced oxytocin levels perform worse on empathy tasks, new research shows

People suffering medical conditions causing low levels of oxytocin perform worse on empathy tasks, according to new research presented today at the Society for Endocrinology annual conference in Brighton.

7 Nov 2016

Endocrine Society issues new guidelines on hypopituitarism

The Endocrine Society today issued a Clinical Practice Guideline that recommends treating insufficient hormone levels in individuals with hypopituitarism by replacing hormones at levels as close to the body's natural patterns as possible.

13 Oct 2016

Blast-related concussions result in hormone changes that lead to poor quality of life among veterans

A study in military veterans finds that explosive blast-related concussions frequently result in hormone changes leading to problems such as sleep disturbances, fatigue, depression and poor quality of life. The research, to be presented Saturday at the Endocrine Society's 98th annual meeting in Boston, evaluated hormone levels in 41 male veterans who had been deployed to Iraq or Afghanistan.

4 Apr 2016

Lilly, Merck announce another immuno-oncology collaboration

Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced another immuno-oncology collaboration that will evaluate abemaciclib (LY2835219), Lilly's cyclin-dependent kinase (CDK) 4 and 6 inhibitor, and Merck's KEYTRUDA (pembrolizumab) in a Phase I study across multiple tumor types.

10 Dec 2015

Lilly, Merck expand oncology clinical trial collaboration

Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced the extension of an existing collaboration to evaluate the safety and efficacy of the combination of Lilly's ALIMTA (pemetrexed for injection) and Merck's KEYTRUDA (pembrolizumab) in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer (NSCLC).

19 Nov 2015

PET/CT may improve differentiation of PTSD from MTBI

Hybrid imaging with positron emission tomography and computed tomography (PET/CT) in the pituitary region of the brain is a promising tool for differentiating military veterans with post-traumatic stress disorder (PTSD) from those with mild traumatic brain injury (MTBI), according to a new study presented at the annual meeting of the Radiological Society of North America (RSNA).

1 Dec 2014

Hypopituitarism News and Research

Further Reading

The impact of viral infections on the human endocrine system

Hypopituitarism and COVID-19 – exploring a possible bidirectional relationship?

POU1F1 gene variant linked to pituitary dwarfism in Karelian Bear Dogs

Individuals taking glucocorticoids are at high risk if infected with COVID-19

Scientists create world’s first model of pituitary disease using human iPS cells

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

CNDA approves KEYTRUDA for treatment of advanced melanoma

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

First-ever treatment for Merkel cell carcinoma receives approval in Japan

Newly-identified autoimmune endocrine disease is caused by thymomas, study finds

People with reduced oxytocin levels perform worse on empathy tasks, new research shows

Endocrine Society issues new guidelines on hypopituitarism

Blast-related concussions result in hormone changes that lead to poor quality of life among veterans

Lilly, Merck announce another immuno-oncology collaboration

Lilly, Merck expand oncology clinical trial collaboration

PET/CT may improve differentiation of PTSD from MTBI

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News